NCT03221348View on ClinicalTrials.gov

A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma

PHASE1UnknownINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

March 31, 2018

Primary Completion Date

October 31, 2019

Study Completion Date

November 30, 2019

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL

CHO-H01

Glyco-engineered anti-CD20 antibody

Sponsors

Lead Sponsor

Cho Pharma Inc.

All Listed Sponsors

lead

Cho Pharma Inc.

INDUSTRY

NCT03221348 - A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma | Biotech Hunter | Biotech Hunter